首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1616085

非鸦片类疼痛治疗市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Non-opioid Pain Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月02日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年全球非鸦片类疼痛治疗市场价值为472亿美元，预计2024年至2032年复合年增长率为7.3%。瘾及其风险。随着越来越多的人面临关节炎、背痛和神经性问题等疾病，对有效疼痛管理药物的需求激增。随着人们越来越转向更安全的疼痛管理方案，对镇痛药和非类固醇抗发炎药等非鸦片类药物的需求显着增加，推动了市场扩张。这一趋势主要是由于患者寻求阿片类药物的替代品以有效缓解疼痛且没有相关风险而推动的。

整个非鸦片类疼痛治疗产业根据药物类别、药物类型、适应症、给药途径、配销通路和地区进行分类。非鸦片类疼痛治疗市场依药物类别细分，包括局部麻醉药、非类固醇抗发炎药、抗忧郁药、止痛药、抗痉挛药等。 NSAIDs 细分市场将在 2023 年引领市场，预计在整个预测期内将保持其主导地位，复合年增长率为 7.1%。非类固醇抗发炎药在治疗肌肉骨骼、发炎和急性疼痛方面的广泛使用和有效性有助于其市场领先地位。

可透过非处方药 (OTC) 和处方购买，拓宽了其可及性。非类固醇抗发炎药物能够减轻疼痛和炎症，且没有鸦片类药物的风险，这使其成为医疗保健提供者和患者的首选。到 2023 年，口腔细分市场将占据 42.9% 的市场份额，并预计在整个分析期内保持领先地位。口服途径的主导地位源自于其便利性、有效性和广泛的可用性。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	472 亿美元
预测值	884 亿美元
复合年增长率	7.3%

许多患者，即使是那些患有急性或严重疼痛的患者，也更喜欢口服药物，因为它们可以快速缓解疼痛并且无需处方。对鸦片类药物风险认知的提高进一步促使消费者转向更安全的口服替代品。因此，口腔领域在疼痛管理中的既定作用以及对非鸦片类药物解决方案不断增长的需求强化了其主导地位。 2023年，美国以192亿美元的估值引领北美非鸦片类疼痛治疗市场，预计未来几年将显着成长。对替代性疼痛管理解决方案的需求明显，这主要是由于持续的阿片类药物危机和慢性疼痛的广泛流行所推动的。美国也因其在非阿片类药物治疗方面的创新而脱颖而出，这得益于其先进的医疗基础设施、强劲的研发投资以及顶级製药公司的存在。

产业生态系统分析
产业影响力
- 成长动力
  - 老年人口增加和对疼痛管理的关注
  - 提高对阿片类药物使用相关风险的认识
  - 扩大研究经费和活动
  - 药物输送系统不断进步
- 产业陷阱与挑战
  - 副作用和安全问题
  - 替代疗法和非药物方法的可用性
成长潜力分析
管道分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
非类固醇类抗发炎药 (NSAID)
局部麻醉剂
抗忧郁药
抗惊厥药
止痛药
其他药物类别

第 6 章：市场估计与预测：按药物类型，2021 - 2032 年

主要趋势
场外交易 (OTC)
处方

第 7 章：市场估计与预测：按指标划分，2021 - 2032 年

主要趋势
神经性疼痛
术后疼痛
慢性背痛
癌症痛
偏头痛
关节炎疼痛
肌肉扭伤/拉伤
其他适应症

第 8 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
口服
专题
可注射
其他给药途径

第 9 章：市场估计与预测：按配销通路，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 10 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Amgen Inc.
Almatica Pharma LLC
Eli Lilly and Company
Fresenius Kabi AG
GlaxoSmithKline plc
Haleon group
Heron Therapeutics
Hyloris Pharmaceuticals
Johnson & Johnson Consumer Inc.
Neumentum Inc.
Novartis AG
Par Pharmaceutical, Inc.
Pfizer Inc.
Sanofi
Scilex Holding Company
Sun Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals
WEX Pharmaceuticals Inc.

简介目录

Product Code: 11178

The Global Non-Opioid Pain Treatment Market was valued at USD 47.2 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2032. This growth can be attributed to the rising incidence of chronic pain conditions and heightened concerns over opioid addiction and its risks. With a growing number of individuals facing disorders like arthritis, back pain, and neuropathic issues, the demand for effective pain management drugs has surged. With a growing shift towards safer pain management options, the demand for non-opioid treatments like analgesics and non-steroidal anti-inflammatory drugs has seen a significant rise, driving market expansion. This trend is largely fueled by patients seeking alternatives to opioids for effective pain relief without the associated risks.

The overall non-opioid pain treatment industry is classified based on drug class, medication type, indication, route of administration, distribution channel, and region. The non-opioid pain treatment market is segmented by drug class, including local anesthetics, NSAIDs, antidepressants, analgesics, anticonvulsants, and others. The NSAIDs segment led the market in 2023 and is projected to maintain its dominance with a CAGR of 7.1% throughout the forecast period. NSAIDs' widespread use and effectiveness in treating musculoskeletal, inflammatory, and acute pain contribute to their market leadership.

Being available both over-the-counter (OTC) and via prescription broadens their accessibility. NSAIDs' capability to alleviate pain and inflammation without the risks tied to opioids has made them a preferred choice for healthcare providers and patients alike. The oral segment, commanding a 42.9% market share in 2023, is poised to retain its lead throughout the analysis period. The oral route's dominance stems from its convenience, effectiveness, and broad availability.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$47.2 Billion
Forecast Value	$88.4 Billion
CAGR	7.3%

Many patients, even those with acute or severe pain, prefer oral medications for their rapid relief and non-prescription nature. Heightened awareness of opioid risks has further nudged consumers towards safer oral alternatives. Consequently, the oral segment's established role in pain management and the rising demand for non-opioid solutions reinforce its dominance. In 2023, the U.S. led the North American non-opioid pain treatment market with a valuation of USD 19.2 billion, and significant growth is anticipated in the coming years.Several pivotal factors underpin the U.S.'s dominance in the North American market. There's a pronounced demand for alternative pain management solutions, largely driven by the ongoing opioid crisis and the widespread prevalence of chronic pain conditions. The U.S. also stands out for its innovation in non-opioid treatments, thanks to its advanced healthcare infrastructure, robust R&D investments, and the presence of top-tier pharmaceutical companies.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising geriatric population and concern for pain management
  - 3.2.1.2 Increasing awareness of the risks associated with opioid use
  - 3.2.1.3 Expanding research funding and activities
  - 3.2.1.4 Growing advancements in the drug delivery system
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects and safety concerns
  - 3.2.2.2 Availability of alternative therapies and non-pharmacological approaches
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.3 Local anesthetics
5.4 Antidepressants
5.5 Anticonvulsants
5.6 Analgesics
5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Over-the-counter (OTC)
6.3 Prescription

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Neuropathic pain
7.3 Post-operative pain
7.4 Chronic back pain
7.5 Cancer pain
7.6 Migraine
7.7 Arthritic pain
7.8 Muscle sprain/strain
7.9 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Topical
8.4 Injectable
8.5 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa